Clinical end points of therapy for patients with mild community-acquired pneumonia.
Approximately 80% of patients with community-acquired pneumonia receive treatment as outpatients. The question is what are valid, reproducible, and quantifiable clinical end points that can be used in prospective clinical trials of the safety and efficacy of antibacterials. Patient-reported outcomes and measurements of time to end point are reasonable methods that, according to the limited data available, appear to work in clinical trials of therapy for mild-to-moderate community-acquired pneumonia among outpatients.
Gilbert
David N
DN
Department of Infectious Diseases, Providence Portland Medical Center, Portland, Oregon 97213, USA. david.gilbert@providence.org
D000900:Anti-Bacterial Agents / Q000009:adverse effects* / Q000627:therapeutic use*; D015415:Biomarkers; D017714:Community-Acquired Infections / Q000188:drug therapy*; D006801:Humans; D018410:Pneumonia, Bacterial / Q000188:drug therapy*; D016896:Treatment Outcome
D000900:Anti-Bacterial Agents; D015415:Biomarkers